AC Immune vs Dianthus Therapeutics
ACIU and DNTH side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How ACIU and DNTH compare
Dianthus Therapeutics scores higher on the StockData Score (7 against 3 for AC Immune), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | ACIU | DNTH |
|---|---|---|
| Size and price | ||
| Market cap | – | $5.0B |
| Share price | $2.26 | $89.30 |
| Change, 1 year | −32.5% | 144% |
| Change, 5 years | −58.7% | −16.6% |
| Beta (5Y) | 1.18 | 1.44 |
| Employees | 122 | 92 |
| StockData Score | ||
| Total score | 3 | 7 (better) |
| Valuation score | 0 | 0 |
| Growth score | 0 | 0 |
| Performance score | 0 | 1 (better) |
| Health score | 3 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/B | – | 4.0× |
| Growth | ||
| Revenue growth (TTM) | −86.9% | – |
| Revenue growth, 5Y average | −25.4% | – |
| Profitability | ||
| Operating margin | −1940% | – |
| FCF margin | −1964% | – |
| Return on equity | – | −22.6% |
| Return on invested capital | – | −22.2% |
| Financial health | ||
| Debt / equity | – | 0.00 |
| Interest coverage | −362.9× | – |
| Current ratio | 0.93 | 30.02 (better) |
| Altman Z-score | – | 85.71 |
| Piotroski F-score | – | 2 |
| Dividends and buybacks | ||
| Dividend yield | – | 0.00% |
| Years of dividend growth | – | 0 |
| Buyback yield | – | −0.01% |
| Shareholder yield | – | −0.01% |
| Ownership | ||
| Held by institutions | – | 118% |
| Held by insiders | 23.6% | 9.1% |
| Insider net buying, 12 months | −$27.9K (better) | −$63.8M |
| Short interest, % of float | – | 18.2% |
Go deeper
- ACIU stock overview
- ACIU income statement
- ACIU valuation and score
- DNTH stock overview
- DNTH income statement
- DNTH valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.